Lung Diseases, Interstitial

Advancements in Pulmonary Hypertension and Interstitial Lung Disease: Emerging Therapies and Clinical Trial Designs

6 months ago talkbio0Tagged Clinical Trials, diagnostic tools, Lung Diseases, Interstitial, Pathogenesis, Phenotype, Pulmonary arterial hypertension, Pulmonary Hypertension

Pulmonary Hypertension (PH), Interstitial Lung Disease (ILD), Pulmonary Arterial Hypertension (PAH), Clinical Trials, Emerging Therapies, Pathogenesis, Phenotypes, Diagnostic Tools

Roivant Sciences Acquires Experimental Pulmonary Hypertension Drug Mosliciguat from Bayer

7 months ago talkbio0Tagged Bayer, Lung Diseases, Interstitial, Mosliciguat, PH-ILD, Pulmonary Hypertension, Pulmovant, Roivant

Roivant Sciences, Pulmovant, Bayer, Mosliciguat, Pulmonary Hypertension, PH-ILD, Interstitial Lung Disease

FDA Grants Tentative Approval for YUTREPIA, a New Treatment for Pulmonary Arterial Hypertension and Pulmonary Hypertension Associated with Interstitial Lung Disease

8 months ago talkbio0Tagged Associated with, Lung Diseases, Interstitial, PH-ILD, Pulmonary arterial hypertension, Pulmonary Hypertension, regulatory exclusivity, Tentative Approval, Tyvaso, United States Food and Drug Administration, United Therapeutics, YUTREPIA

YUTREPIA, treprostinil, pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), FDA tentative approval, regulatory exclusivity, United Therapeutics, Tyvaso